Last reviewed · How we verify
Td1aP
Td1aP is a combined diphtheria-tetanus-acellular pertussis vaccine that stimulates immune responses against three bacterial pathogens.
Td1aP is a combined diphtheria-tetanus-acellular pertussis vaccine that stimulates immune responses against three bacterial pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | Td1aP |
|---|---|
| Also known as | diTekiBooster |
| Sponsor | Swedish Institute for Infectious Disease Control |
| Drug class | Vaccine (toxoid and acellular) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This vaccine contains inactivated toxoids of Corynebacterium diphtheriae and Clostridium tetani, along with acellular components of Bordetella pertussis. It works by inducing both humoral and cellular immune responses, generating antibodies and memory cells that protect against diphtheria, tetanus, and pertussis infections.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Td1aP CI brief — competitive landscape report
- Td1aP updates RSS · CI watch RSS
- Swedish Institute for Infectious Disease Control portfolio CI